Category Archives: Stem Cell Therapy

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly owned subsidiary Lifeline Skin Care, Inc. ("LSC"), has now completed its evaluation of the highly successful trial launch of its new stem cell skin care product line in November and December 2010, and will move forward with its general marketing program.

Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with world recognized cosmetic chemists. The breakthrough products deliver leading advances in skin rejuvenation technology that help to prevent and repair damaged skin. The products are available through our online store at http://www.lifelineskincare.com.

"Sales to date have greatly exceeded our expectations for the trial launch. These initial sales resulted from a very limited product offering made to subscribers of only one of the several newsletters of our marketing partner, John Mauldin, plus a small direct mailing to interested parties and ISCO's shareholders who had signed up for general corporate information through the ISCO website," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

Lifeline Skin Care is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by John Mauldin's specialty Internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved."

Kenneth Aldrich, Chairman of ISCO, issued a cautionary comment to its investors. "We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."

ISCO investors should note that under ISCO's current revenue recognition policy, a large portion of the Q-4 2010 sales will not be included as revenue in the financial statements for the year ended December 31, 2010. Sales of these products meet our revenue recognition criteria after our 30 day product guarantee period has been completed.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product marketing plans, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Original Article Source - Mass High Tech

Advanced Cell Technology Inc. has been given a patent for its nondestructive technique of obtaining human embryonic stem cell (hESC) lines. Called “single-blastomere” technology, the technique was referred to in a statement by ACT interim chairman and CEO Gary Rabin as “one of the most significant” among the Marlborough biotech’s more than 150 patents and patent applications.

“It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology,” Rabin said, in the statement.

ACT (OTCBB: ACTC) said in a news release that its single-blastomere technique avoids embryo destruction by using a one-cell biopsy approach.

In January, the company pulled in a $25 million financing and was cleared by the FDA for its Investigational New Drug application to use hESCs in treating Dry Age-Related Macular Degeneration.

Rabin has been serving in his interim roles at ACT since mid-December, when William M. Caldwell IV, then chairman and CEO, died unexpectedly. Caldwell had held the CEO role of ACT since 2005 and the chairman post since 2006.